Search Tag: preserved ejection fraction
2021 27 Aug
In a Hot Line Session at the ESC Congress 2021, the results of the EMPEROR-Preserved trial were presented that demonstrated a significant reduction in composite cardiovascular endpoints in patients with heart failure and preserved ejection fraction. This was a pooled analysis of two randomised trials that investigated the beneficial effects of...Read more
2019 10 Aug
Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September. The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator...Read more
2019 03 Aug
Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September. The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator...Read more